ArticleCancer cell2018
Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 216 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
216citing papers in PubMed, 3 pooled it
19.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
216 citing papers in PubMed, 3 syntheses or guidelines pooled it, 316 citations in OpenAlex.
- Aging and prostate health: meta-analytic insights into age-related prostatic disorders.Frontiers in oncology · 2026Pooled it
- Integration of single-cell and bulk RNA-sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer.Molecular oncology · 2025Pooled it
- HER2Ile655Val Single Nucleotide Polymorphism Associated with Early-Onset Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2021Pooled it
- The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer.Nature communications · 2026Article
- IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states.EMBO molecular medicine · 2026Article
- Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.Nature communications · 2026Article
- Article
- Androgen receptor drives divergent chromatin accessibility programs in benign and malignant prostate epithelial cells.Nucleic acids research · 2026Article
- Histone chaperone HIRA restrains ferroptosis susceptibility through epigenetic control of iron metabolism in prostate cancer.Science China. Life sciences · 2026Article
- Multi-omics dissection of FOXA1 reveals cancer-type-specific transcriptional networks and functional risk variants.iScience · 2026Article
- Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival.bioRxiv : the preprint server for biology · 2026Article
- Early-Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection.MedComm · 2026Review
- PDIA1 promotes androgen receptor activation and prostate cancer cell survival through enhancing HMMR stability.FEBS letters · 2026Article
- Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
- Single-Cell Analysis Reveals Pre-Existing Basal-Associated Epithelial States in Metastatic Hormone-Naïve Prostate Cancer.International journal of molecular sciences · 2026Article
- APOBEC3A is the predominant global editor of cytosines in human mRNAs and in single-strand RNA viruses.G3 (Bethesda, Md.) · 2026Article
- Transcriptional network analysis of PTEN-protein-deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication.Molecular oncology · 2026Article
- CCDC78 is required for prostate cancer cell growth and serves as a prognostic biomarker for high-risk disease.Discover oncology · 2026Article
- Motif-Centered Analyses Reveal Universal and Tissue-Specific Mutagenic Mechanisms Operating in the Human Body.bioRxiv : the preprint server for biology · 2026Article
- Co-Targeting Nuclear Export and Translation Initiation Uncovers a Therapeutic Vulnerability in Lethal Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
156 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
55 authors at 17 institutions in 6 countries.
Clarissa GerhauserDivision of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Francesco FaveroFinsen Laboratory, Rigshospitalet, DK-2200, Copenhagen, Denmark; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark.
Thomas RischMax Planck Institute for Molecular Genetics, Otto Warburg Laboratory Gene Regulation and Systems Biology of Cancer, Ihnestrasse 63-73, 14195 Berlin, Germany.
Ronald SimonDepartment of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Lars FeuerbachDivision Applied Bioinformatics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Yassen AssenovDivision of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Doreen HeckmannDivision of Cancer Genome Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
Nikos SidiropoulosFinsen Laboratory, Rigshospitalet, DK-2200, Copenhagen, Denmark; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark.
Sebastian M WaszakEuropean Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69120 Heidelberg, Germany.
Daniel HübschmannDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Department for Bioinformatics and Functional Genomics, Institute of Pharmacy and Molecular Biotechnology and Bioquant, University of Heidelberg, Heidelberg 69120, Germany; Department of Pediatric Immunology, Hematology and Oncology, University Hospital, Heidelberg 69120, Germany.
Alfonso UrbanucciCentre for Molecular Medicine Norway, Nordic European Molecular Biology Laboratory Partnership, Forskningsparken, University of Oslo, 0316 Oslo, Norway; Institute for Cancer Genetics and Informatics, Oslo University Hospital, 0316 Oslo, Norway; Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, 0316 Oslo, Norway.
Etsehiwot G GirmaFinsen Laboratory, Rigshospitalet, DK-2200, Copenhagen, Denmark; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark.
Vladimir KuryshevDivision of Cancer Genome Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
Leszek J KlimczakIntegrative Bioinformatics Support Group, National Institute of Environmental Health Sciences, Durham, 27709 NC, USA.
Natalie SainiGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, Durham, 27709 NC, USA.
Adrian M StützEuropean Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69120 Heidelberg, Germany.
Dieter WeichenhanDivision of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Lisa-Marie BöttcherDepartment of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Reka TothDivision of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Josephine D HendriksenFinsen Laboratory, Rigshospitalet, DK-2200, Copenhagen, Denmark; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark.
Christina KoopDepartment of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Pavlo LutsikDivision of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Sören MatzkMax Planck Institute for Molecular Genetics, Otto Warburg Laboratory Gene Regulation and Systems Biology of Cancer, Ihnestrasse 63-73, 14195 Berlin, Germany.
Hans-Jörg WarnatzMax Planck Institute for Molecular Genetics, Otto Warburg Laboratory Gene Regulation and Systems Biology of Cancer, Ihnestrasse 63-73, 14195 Berlin, Germany.
Vyacheslav AmstislavskiyMax Planck Institute for Molecular Genetics, Otto Warburg Laboratory Gene Regulation and Systems Biology of Cancer, Ihnestrasse 63-73, 14195 Berlin, Germany.
Clarissa FeuersteinDivision of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.
Benjamin RaederEuropean Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69120 Heidelberg, Germany.
Olga BogatyrovaDivision of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Eva-Maria SchmitzPROGETHER Prostate Cancer Network, 0316 Oslo, Norway.
Claudia Hube-MaggDepartment of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Martina KluthDepartment of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Hartwig HulandMartini-Clinic Prostate Cancer Center at the University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany.
Markus GraefenMartini-Clinic Prostate Cancer Center at the University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany.
Chris LawerenzDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Gervaise H HenryDepartment of Urology, UT Southwestern Medical Center, Dallas, TX 75390-9110, USA.
Takafumi N YamaguchiInformatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Alicia MalewskaDepartment of Urology, UT Southwestern Medical Center, Dallas, TX 75390-9110, USA.
Jan MeinersDepartment of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Daniela SchillingDivision of Cancer Genome Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; NCT Trial Center, National Center for Tumor Diseases and German Cancer Research Center, 69120 Heidelberg, Germany.
Eva ReisingerDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Roland EilsDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Department for Bioinformatics and Functional Genomics, Institute of Pharmacy and Molecular Biotechnology and Bioquant, University of Heidelberg, Heidelberg 69120, Germany.
Matthias SchlesnerDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Bioinformatics and Omics Data Analytics (B240), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
Douglas W StrandDepartment of Urology, UT Southwestern Medical Center, Dallas, TX 75390-9110, USA.
Robert G BristowManchester Cancer Research Centre, University of Manchester, 555 Wilmslow Road, Manchester, UK.
Paul C BoutrosOntario Institute for Cancer Research, Toronto, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Canada.
Christof von KalleGerman Cancer Consortium (DKTK), 69120 Heidelberg, Germany; Division of Translational Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Dmitry GordeninGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, Durham, 27709 NC, USA.
Holger SültmannDivision of Cancer Genome Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
Benedikt BrorsDivision Applied Bioinformatics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
Guido SauterDepartment of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Christoph PlassDivision of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
Marie-Laure YaspoMax Planck Institute for Molecular Genetics, Otto Warburg Laboratory Gene Regulation and Systems Biology of Cancer, Ihnestrasse 63-73, 14195 Berlin, Germany.
Jan O KorbelEuropean Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69120 Heidelberg, Germany. Electronic address: korbel@embl.de.
Thorsten SchlommMartini-Clinic Prostate Cancer Center at the University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany; Charité Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin, Germany. Electronic address: thorsten.schlomm@charite.de.
Joachim WeischenfeldtFinsen Laboratory, Rigshospitalet, DK-2200, Copenhagen, Denmark; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark; European Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69120 Heidelberg, Germany; Charité Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin, Germany. Electronic address: joachim.weischenfeldt@bric.ku.dk.
Heidelberg University · DEEuropean Molecular Biology Laboratory · DEMax Planck Institute for Molecular Genetics · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversität Hamburg · DEDeutschen Konsortium für Translationale Krebsforschung · DENational Institute of Environmental Health Sciences · USThe University of Texas Southwestern Medical Center · USEpigenomics (Germany) · DEGerman Cancer Research Center · DEOntario Institute for Cancer Research · CARigshospitalet · DKUniversity of Copenhagen · DKMartini-Klinik · DENational Center for Tumor Diseases · DEOslo University Hospital · NOUniversity of Manchester · GB
Funding
Genome-wide hypermutation and structural instabilityZIAES103266 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI GORDENIN, DMITRY · 2015 to 2025
$18.0MMechanisms of Fatty Acid Metabolism in Prostate Differentiation and DiseaseK01DK098277 · NIDDK · VANDERBILT UNIVERSITY · PI STRAND, DOUGLAS WILLIAM · 2013 to 2017
$640kInterplay Between Stem Cells and Inflammation in Benign Prostatic HyperplasiaR03DK110497 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI STRAND, DOUGLAS WILLIAM · 2016 to 2017
$162kIntramural NIH HHS Z99 ES999999NIDDK NIH HHS K01 DK098277NIDDK NIH HHS R03 DK110497
Abstract
Identifying the earliest somatic changes in prostate cancer can give important insights into tumor evolution and aids in stratifying high- from low-risk disease. We integrated whole genome, transcriptome and methylome analysis of early-onset prostate cancers (diagnosis ≤55 years). Characterization across 292 prostate cancer genomes revealed age-related genomic alterations and a clock-like enzymatic-driven mutational process contributing to the earliest mutations in prostate cancer patients. Our integrative analysis identified four molecular subgroups, including a particularly aggressive subgroup with recurrent duplications associated with increased expression of ESRP1, which we validate in 12,000 tissue microarray tumors. Finally, we combined the patterns of molecular co-occurrence and risk-based subgroup information to deconvolve the molecular and clinical trajectories of prostate cancer from single patient samples.
Indexed as
DNA MethylationGene Expression Regulation, NeoplasticTranscriptomeAdultBiomarkers, TumorEvolution, MolecularHumansMaleMiddle AgedMutationProstatic NeoplasmsRisk FactorsRNA-Binding ProteinsWhole Genome SequencingBiomarkers, TumorESRP1 protein, humanRNA-Binding ProteinsAPOBECcancer genomicsearly-onset cancerepigenetic risk-scoremutational processesprostate cancerstructural variantstumor evolutiontumor evolution prediction
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.